Ultragenyx Pharmaceutical’s (RARE) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Ultragenyx Pharmaceutical (NASDAQ:RARE) in a report issued on Wednesday morning,Benzinga reports. They currently have a $118.00 target price on the biopharmaceutical company’s stock. Cantor Fitzgerald also issued estimates for Ultragenyx Pharmaceutical’s FY2025 earnings at ($4.44) EPS.

A number of other equities research analysts have also recently commented on the company. Canaccord Genuity Group reissued a “buy” rating and issued a $121.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, November 12th. Wells Fargo & Company lifted their price target on shares of Ultragenyx Pharmaceutical from $75.00 to $88.00 and gave the company an “overweight” rating in a research report on Friday, December 20th. Wedbush restated a “neutral” rating and set a $48.00 price objective (up previously from $46.00) on shares of Ultragenyx Pharmaceutical in a report on Monday, January 13th. Piper Sandler lifted their price objective on shares of Ultragenyx Pharmaceutical from $135.00 to $140.00 and gave the company an “overweight” rating in a report on Monday, January 13th. Finally, HC Wainwright restated a “buy” rating and issued a $95.00 target price on shares of Ultragenyx Pharmaceutical in a report on Tuesday, December 24th. One equities research analyst has rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $92.43.

Ultragenyx Pharmaceutical Stock Down 1.8 %

NASDAQ:RARE opened at $44.05 on Wednesday. Ultragenyx Pharmaceutical has a twelve month low of $37.02 and a twelve month high of $60.37. The company has a fifty day moving average of $44.56 and a 200-day moving average of $49.57. The firm has a market capitalization of $4.07 billion, a P/E ratio of -6.81 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.45) by $0.05. The firm had revenue of $139.49 million during the quarter, compared to the consensus estimate of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The business’s revenue was up 42.3% compared to the same quarter last year. During the same period in the previous year, the firm posted ($2.23) earnings per share. On average, analysts anticipate that Ultragenyx Pharmaceutical will post -6.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 11,727 shares of the business’s stock in a transaction dated Monday, December 30th. The shares were sold at an average price of $42.23, for a total value of $495,231.21. Following the transaction, the chief executive officer now directly owns 2,183,985 shares in the company, valued at $92,229,686.55. The trade was a 0.53 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders own 5.80% of the company’s stock.

Institutional Trading of Ultragenyx Pharmaceutical

A number of large investors have recently bought and sold shares of the company. Algert Global LLC raised its stake in Ultragenyx Pharmaceutical by 46.9% in the 3rd quarter. Algert Global LLC now owns 73,902 shares of the biopharmaceutical company’s stock valued at $4,105,000 after acquiring an additional 23,580 shares during the period. Frazier Life Sciences Management L.P. purchased a new position in shares of Ultragenyx Pharmaceutical in the second quarter worth about $17,468,000. Bamco Inc. NY bought a new stake in shares of Ultragenyx Pharmaceutical in the third quarter valued at approximately $2,666,000. Principal Financial Group Inc. lifted its stake in shares of Ultragenyx Pharmaceutical by 740.0% during the 3rd quarter. Principal Financial Group Inc. now owns 86,440 shares of the biopharmaceutical company’s stock valued at $4,802,000 after buying an additional 76,150 shares in the last quarter. Finally, Clearline Capital LP bought a new position in Ultragenyx Pharmaceutical in the 2nd quarter worth approximately $1,355,000. 97.67% of the stock is owned by hedge funds and other institutional investors.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.